| Literature DB >> 33570645 |
Kennosuke Karube1, Mitsuyoshi Takatori1, Shugo Sakihama1, Yuma Tsuruta2, Takashi Miyagi3, Kazuho Morichika4, Sakiko Kitamura4, Norihiro Nakada2, Masaki Hayashi5, Shohei Tomori5, Iwao Nakazato2, Kazuiku Ohshiro6, Naoki Imaizumi7, Yara Yukie Kikuti8, Naoya Nakamura8, Satoko Morishima4, Hiroaki Masuzaki4, Takuya Fukushima9.
Abstract
Hodgkin and Reed-Sternberg (HRS) cells, a hallmark of classic Hodgkin lymphoma (CHL), are occasionally detected in non-Hodgkin lymphomas, including adult T-cell leukemia/lymphoma (ATLL), a lymphoid neoplasm caused by human T-cell leukemia virus type 1 (HTLV-1). HRS-like cells associated with ATLL have been described to be of B-cell lineage and infected with Epstein-Barr virus (EBV), not HTLV-1. We herein describe clinicopathological findings in 8 cases (4 males and 4 females; median age, 73 years [range, 55-81 years]) of ATLL with HTLV-1-infected HRS-like cells identified by ultrasensitive RNA in situ hybridization for HTLV-1 basic leucine zipper factor (HBZ-ISH), a specific viral transcript of HTLV-1. All patients showed nodal or mediastinal lesions, and 5 of the 8 patients were at an advanced disease stage. HRS-like cells were positive for CD30, CD15, MUM1, CD25, and HBZ-ISH and negative for B-cell markers, including PAX5, pan-T-cell antigens, and EBV in all cases. Five cases were positive for CD4, and 6 cases were positive for fascin. HBZ was identified in both HRS-like cells and surrounding lymphoid cells in 1 case with an aggressive clinical course and only HRS-like cells in 7 cases, most of whom showed a clinical response regardless of the chemotherapeutic regimen. Even though the definitive lineage typing of the HTLV-1-infected HRS cells is one of the limitations of this study in the absence of single-cell microdissection for polymerase chain reaction analysis, the combination of diffuse HBZ-ISH positivity and negativity for PAX5 and EBV deemed these cases distinct from CHL arising in HTLV-1 carriers.Entities:
Mesh:
Year: 2021 PMID: 33570645 PMCID: PMC7805330 DOI: 10.1182/bloodadvances.2020003201
Source DB: PubMed Journal: Blood Adv ISSN: 2473-9529